natgillin/translations-raw huggingface dataset:
Zinplava is a medicine used in adults who have infections due to bacteria called Clostridium difficile that cause severe diarrhoea. 
Zdravilo Zinplava se uporablja pri odraslih, pri katerih so prisotne okužbe zaradi bakterije, imenovane Clostridium difficile, ki povzroča hudo drisko.
In the first study, 17% of patients given Zinplava (67 out of 386) had a new episode of diarrhoea in the 12 weeks after treatment compared with 28% of patients given placebo (109 out of 395). 
V prvi študiji je 17 % (67 od 386) bolnikov, zdravljenih z zdravilom Zinplava, v 12 tednih po zdravljenju doživelo novo epizodo driske, pri bolnikih, ki so prejemali placebo, pa je bilo takih bolnikov 28 % (109 od 395).
For the full list of all side effects and restrictions with Zinplava, see the package leaflet. 
Za celoten seznam vseh neželenih učinkov in omejitev pri uporabi zdravila Zinplava glejte navodilo za uporabo.
Zinplava is available as a concentrate to be made into a solution for infusion (drip) into a vein. 
Zdravilo Zinplava je na voljo v obliki koncentrata za pripravo raztopine za infundiranje (kapalne infuzije) v veno.
It is used to prevent future episodes of diarrhoea in patients who are taking antibiotics to treat their C. difficile infection and who are at high risk of the infection coming back. 
Uporablja se za preprečevanje ponovnih epizod driske pri bolnikih, ki za zdravljenje okužbe z bakterijo C. difficile jemljejo antibiotike in pri katerih obstaja visoko tveganje ponovitve okužbe.
Zinplava is generally well tolerated with side effects similar to those observed in patients on placebo. 
Bolniki v splošnem dobro prenašajo zdravilo Zinplava, katerega neželeni učinki so podobni tistim, opaženim pri bolnikih, ki so prejemali placebo.
C. difficile bacteria produce toxins that damage the lining of the gut causing diarrhoea which may be severe. 
Bakterija C. difficile izdeluje toksine, ki lahko poškodujejo sluznico prebavil; to povzroča drisko, ki je lahko huda.
How does Zinplava work? 
Kako zdravilo Zinplava deluje?
How is Zinplava used? 
Kako se zdravilo Zinplava uporablja?
Zinplava given during antibiotic treatment was shown to be more effective than placebo (a dummy treatment) at preventing a new episode of diarrhoea caused by C. difficile infection in 2 main studies involving a total of 2,655 patients. 
V dveh glavnih študijah, ki sta vključevali skupaj 2 655 bolnikov, je bilo dokazano, da je zdravilo Zinplava, dano med zdravljenjem z antibiotiki, pri preprečevanju nove epizode driske, ki jo povzroča okužba z bakterijo C. difficile, učinkovitejše od placeba (zdravila brez zdravilne učinkovine).
21 October 2010 
21. oktober 2010
Intrinsa has been authorised since July 2006. 
Zdravilo Intrinsa je odobreno od julija 2006.
The full European Public Assessment Report for Intrinsa can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila Intrinsa je na voljo na spletni strani agencije ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
The application was withdrawn after ‘day 90'. 
Družba je vlogo umaknila po „90.
The main measure of effectiveness was based on how frequently the women had ‘satisfying sexual episodes'. 
Glavno merilo učinkovitosti je bila pogostnost „zadovoljivih spolnih odnosov“ pri ženskah.
This means that the CHMP had evaluated the documentation provided by the company and formulated two lists of questions. 
To pomeni, da je CHMP ocenil dokumentacijo, ki jo je predložila družba, in oblikoval dva seznama vprašanj.
What is happening with Intrinsa for its existing indication? 
Kaj se dogaja z zdravilom Intrinsa za obstoječe indikacije?
The letter from the company notifying the Agency of the withdrawal of the application is available under the tab ‘All documents'. 
Dopis, s katerim družba agencijo obvešča o umiku vloge, je na voljo pod zavihkom „All documents“ (vsi dokumenti).
What consequences does this withdrawal have for patients in clinical trials or compassionate use programmes? 
Kakšne so posledice tega umika za bolnike, ki sodelujejo v kliničnih preskušanjih ali programih sočutne uporabe zdravila?
These women will also be receiving treatment with an oestrogen (a female sex hormone). 
Te ženske se zdravijo tudi z estrogenom (ženski spolni hormon).
The amount of testosterone in the blood is reduced after the menopause. 
Količina testosterona v krvi se po menopavzi zniža.
The CHMP noted that there was insufficient long-term data on the safety of the medicine in this larger group of patients and was therefore of the opinion that the medicine's benefits in these women did not outweigh its risks. 
CHMP je menil, da ni zadostnih podatkov o dolgoročni varnosti zdravila pri tej večji skupini bolnic, in izrazil mnenje, da koristi zdravila pri teh ženskah ne odtehtajo njegovih tveganj.
The company presented results of four studies in a total of 2,245 women with HSDD. 
Družba je predstavila rezultate štirih študij, v katerih je sodelovalo 2 245 žensk z motnjo hipoaktivne spolne želje.
The active substance in Intrinsa, testosterone, is a natural sex hormone produced in men and, to a lesser extent, in women. 
Zdravilna učinkovina v zdravilu Intrinsa, testosteron, je naravni spolni hormon, ki ga proizvajajo moški in v manjši meri tudi ženske.
The patch releases 300 micrograms of the active substance testosterone over 24 hours. 
Obliž v 24 urah sprosti 300 mikrogramov zdravilne učinkovine testosteron.
On 22 September 2010, Warner Chilcott Pharmaceuticals UK Limited officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a change to the marketing authorisation for Intrinsa, to extend treatment to all postmenopausal women with hypoactive sexual desire disorder. 
Družba Warner Chilcott Pharmaceuticals UK Limited je dne 22. septembra 2010 uradno obvestila Odbor za zdravila za uporabo v humani medicini (CHMP), da želi umakniti vlogo za spremembo dovoljenja za promet z zdravilom Intrinsa, namenjenim daljšemu zdravljenju žensk po menopavzi z motnjo hipoaktivne spolne želje.
The company informed the CHMP that there are no consequences for patients currently in clinical trials or compassionate use programmes with Intrinsa. 
Družba je obvestila CHMP, da umik nima nobenih posledic za bolnice, ki trenutno sodelujejo v kliničnih preskušanjih ali programih sočutne uporabe zdravila Intrinsa.
They were given either Intrinsa or placebo (a dummy treatment). 
Dajali so jim zdravilo Intrinsa ali placebo (zdravilo brez zdravilne učinkovine).
Intrinsa is a transdermal patch (a patch that delivers a medicine across the skin). 
Zdravilo Intrinsa je transdermalni obliž (obliž, ki dovaja zdravilo skozi kožo).
It is already used to treat women with hypoactive sexual desire disorder (HSDD, a lack of sexual thoughts and sexual desire) who have had their womb and both ovaries surgically removed. 
Uporablja se za zdravljenje žensk z motnjo hipoaktivne spolne želje (HSDD, pomanjkanje spolnih misli in spolnega poželenja), ki so jim kirurško odstranili maternico in oba jajčnika.
Low testosterone levels have been linked to low sexual desire and to reduced sexual thoughts and arousal. 
Nizke ravni testosterona so povezane z majhnim spolnim poželenjem ter
Based on the review of the data and the company's response to the CHMP's lists of questions, at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Intrinsa could not have been approved for use in all postmenopausal women who have HSDD. 
Na podlagi pregleda podatkov in odgovorov družbe na seznam vprašanj, ki jih je zastavil CHMP, je Odbor v času umika vloge izrazil določene zadržke in začasno menil, da zdravila Intrinsa ni mogoče odobriti za zdravljenje vseh žensk po menopavzi z motnjo hipoaktivne spolne želje.
In postmenopausal women, Intrinsa was expected to release testosterone through the skin into the bloodstream to produce testosterone levels that match the levels seen before the menopause. 
Pri ženskah po menopavzi naj bi zdravilo Intrinsa sproščalo testosteron skozi kožo v krni obtok in tako zagotavljalo takšno raven testosterona, kot je bila prisotna pred menopavzo.
What is Intrinsa? 
Kaj je zdravilo Intrinsa?
This was to incude all women who have been through the menopause and not only those who are ‘surgically postmenopausal' as result of having had their womb or ovaries removed. 
To naj bi vključevalo vse ženske po menopavzi in ne le tistih, ki so v menopavzi zaradi kirurške odstranitve maternice ali jajčnikov.
What was Intrinsa expected to be used for? 
Za kaj naj bi se zdravilo Intrinsa uporabljalo?
Some of the women had their womb and both ovaries surgically removed while others were postmenopausal women who had not had their womb or ovaries removed. 
Nekaterim sodelujočim ženskam so kirurško odstranili maternico in oba jajčnika, druge ženske pa so bile po menopavzi, vendar jim maternice ali jajčnikov niso odstranili.
How is Intrinsa expected to work? 
Kako naj bi zdravilo Intrinsa delovalo?
Intrinsa is expected to work in the same way as it does in women who have had their womb and both ovaries surgically removed. 
Zdravilo Intrinsa naj bi delovalo na enak način kot pri ženskah, pri katerih so kirurško odstranili maternico in oba jajčnika.
Intrinsa was expected to be used to treat HSDD in postmenopausal women with or without hormone treatment. 
Zdravilo Intrinsa naj bi se uporabljalo za zdravljenje motnje hipoaktivne spolne želje pri ženskah po menopavzi, ki se ali se ne zdravijo s hormonsko terapijo.
There are no consequences on the use of Intrinsa in the treatment of HSDD in women who have had their womb and both ovaries removed. 
Za zdravljenje žensk z motnjo hipoaktivne spolne želje, ki so jim odstranili maternico in oba jajčnika, glede uporabe zdravila Intrinsa ni posledic.
The company wanted the authorisation to be granted in Austria, Belgium, Bulgaria, the Czech Republic, Denmark, Estonia, France, Germany, Italy, Latvia, Lithuania, Luxembourg, Norway, Poland, Portugal, Slovakia, Slovenia and Spain (the concerned Member States). 
Družba je želela, da se dovoljenje odobri v Avstriji, Belgiji, Bolgariji, Češki republiki, na Danskem, v Estoniji, Franciji, Nemčiji, Italiji, Latviji, Litvi, Luksemburgu, na Norveškem, Poljskem, Portugalskem, Slovaškem, v Sloveniji in Španiji (zadevne države članice).
1 Article 29 of Directive 2001/83/EC as amended, referral on the grounds of potential serious risk to public health 
1 Člen 29 Direktive 2001/83/ES, kot je bila spremenjena, o napotitvi na podlagi možnega resnega tveganja za javno zdravje.
Ref. EMEA/CHMP/191900/2009 EMEA/H/A-29/1096 
: EMEA/189590/2009 EMEA/H/A-29/1096
As a result the cells cannot multiply. 
Celice se posledično ne morejo več deliti.
The CHMP assessed the available data in order to establish whether the two indications can be supported. 
Odbor CHMP je ovrednotil razpoložljive podatke, da bi ugotovil, ali je mogoče zadevni indikaciji podpreti.
The review was carried out under an ‘Article 29' referral1 procedure. 
Pregled se je opravil v okviru napotitvenega postopka v skladu s členom 291.
Germany considered that the submitted data was insufficient for granting a marketing authorisation for the proposed indications. 
Nemčija je menila, da predloženi podatki niso bili zadostni za odobritev dovoljenja za promet z zdravilom za predlagane indikacije.
Why was Bleomycin reviewed? 
Zakaj je bilo zdravilo Bleomycin pregledano?
On 3 November 2008, the Netherlands medicines regulatory agency, the Medicines Evaluation Board, referred the matter to the CHMP. 
Nizozemska regulatorna agencija za zdravila, Odbor za vrednotenje zdravil, je 3. novembra 2008 zadevo napotila na CHMP.
The RMS and the other positive CMSs were in favour of retaining these indications. 
Referenčna država članica in druge pozitivne zadevne države članice so naklonjene ohranitvi teh indikacij.
The grounds for the referral were that Germany was not in a position to accept some of the anti-cancer indications because they were not recognised as acceptable for bleomycin in the country. 
Razlogi za napotitev so bili, ker Nemčija ni mogla sprejeti nekaterih indikacij proti raku, saj jih ne priznava kot sprejemljive za bleomicin.
What is Bleomycin? 
Kaj je zdravilo Bleomycin?
Questions and answers on the referral for Bleomycin, powder for solution for injection, 15 U/Vial, from Pharmachemie BV 
Vprašanja in odgovori v zvezi z napotitvijo za zdravilo Bleomycin, prašek za raztopino za injiciranje, 15 e/vialo, družbe Pharmachemie BV
Bleomycin is an anti-cancer medicine used to treat certain forms of cancer of the head or the neck, cervix (the neck of the womb) and external sexual organs; certain forms of lymphoma (cancer of the lymphatic system) such as Hodgkin's disease; and to treat cancer of the testicles. 
Bleomycin je zdravilo proti raku, ki se uporablja za zdravljenje določenih oblik raka glave ali vratu, cerviksa (materničnega vratu) in zunanjih spolovil, nekaterih oblik limfoma (raka limfnega sistema), kot je Hodgkinova bolezen, ter raka testisov.
The indications ‘head and neck carcinoma' and ‘epidermoid carcinoma of external genitalia such as penile carcinoma, or cervix' had been deleted from the authorised indications for all bleomycin-containing products in Germany because the balance of benefit/risk for bleomycin in these indications was considered negative. 
Indikaciji „karcinom glave in vratu“ ter „epidermoidni karcinom zunanjih spolovil, kot je karcinom penisa ali cerviksa“, sta bili v Nemčiji izbrisani iz odobrenih indikacij za vsa zdravila, ki vsebujejo bleomicin, ker se je menilo, da je razmerje med koristmi in tveganji za bleomicin pri teh indikacijah negativno.
Bleomycin is almost always used in combination with anti-cancer drugs or in combination with radiation. 
Zdravilo Bleomycin se skoraj vedno uporablja v kombinaciji z zdravili proti raku ali z obsevanjem.
The European Medicines Agency (EMEA) has completed a referral procedure following a disagreement among Member States of the European Union regarding the authorisation of the medicine Bleomycin injection, from Pharmachemie BV. 
Evropska agencija za zdravila (EMEA) je končala napotitveni postopek, do katerega je prišlo po nesoglasju med državami članicami Evropske unije glede odobritve zdravila Bleomycin, injekcija, družbe Pharmachemie BV.
Pharmachemie BV submitted a Marketing Authorisation Application for Bleomycin powder for solution for injection 15 U/vial in the decentralised procedure on 10 July 2007, the Netherlands acting as the reference member state. 
Družba Pharmachemie BV je vlogo za pridobitev dovoljenja za promet z zdravilom Bleomycin, prašek za raztopino za injiciranje, 15 e/vialo, predložila po decentraliziranem postopku dne 10. julija 2007, pri tem pa je Nizozemska prevzela vlogo referenčne države članice.
Based on evaluation of the currently available data, including published literature and current treatment guidelines, and the scientific discussion within the Committee, the CHMP concluded that the benefits of Bleomycin injection, from Pharmachemie BV, outweigh its risks, and therefore the marketing authorisation for Bleomycin should be granted in all concerned member states. 
Na podlagi vrednotenja trenutno razpoložljivih podatkov, vključno z objavljeno literaturo in trenutno veljavnimi smernicami za zdravljenje, ter znanstvene razprave znotraj CHMP je ta zaključil, da koristi zdravila Bleomycin, injekcija, družbe Pharmachemie BV odtehtajo njegova tveganja ter da je zato treba dovoljenje za promet z zdravilom Bleomycin odobriti v vseh zadevnih državah članicah.
Bleomycin can also be used by injection directly inside the chest cavity to treat fluid accumulation in the lungs as a result of cancer. 
Zdravilo Bleomycin se lahko injicira neposredno v prsno votlino za zdravljenje pojava tekočine, ki se v pljučih nabira kot posledica raka.
The Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that the benefits of Bleomycin injection, from Pharmachemie BV, outweigh its risks, and the marketing authorisation can be granted in the Member States of the European Union and the European Economic Area. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji EMEA je zaključil, da koristi zdravila Bleomycin, injekcija, družbe Pharmachemie BV odtehtajo njegova tveganja in da se dovoljenje za promet z zdravilom lahko odobri v državah članicah Evropske unije in Evropskega gospodarskega prostora.
Referral start date: 
Datum začetka postopka napotitve: 20. november 2008 Datum izdaje mnenja:
Bleomycin inserts itself within the strands of DNA, the genetic material of cells, making the strands break. 
Zdravilo Bleomycin se vrine v verige DNK, tj. genetsko gradivo celice, ki se začne zaradi zdravila trgati.
Because consensus could not be reached, the procedure was 
Postopek je bil napoten na odbor CHMP, ker ni bilo mogoče doseči soglasja.
Bleomycin is a cytostatic substance; this means that it stops the growth of cells. 
Zdravilo Bleomycin je citostatična spojina.
40 IU/ml Solution for injection 
raztopina za injiciranje raztopina za injiciranje
EMEA/436209/2008 
EMEA/436209/2008-SL
• The benefit/risk balance of the product was shown to be positive, however in young animals, the summary of Product Characteristics should state that the product is not to be used in neonates or very young calves of less than 2 weeks of age nor in piglets of less than 4 weeks of age. 
• Razmerje med koristmi in tveganji se je pokazalo kot pozitivno, kljub temu pa je v povzetku glavnih značilnosti zdravila za uporabo pri mladih živalih potrebno navesti, da zdravilo ni namenjeno uporabi pri komaj skotenih ali zelo mladih teletih, starih manj kot dva tedna, ter pri pujskih, starih manj kot štiri tedne.
The CVMP Opinion was adopted on 16 July 2008 and the subsequent Commission Decision adopted on 26 September 2008. 
Mnenje Odbora za zdravila za uporabo v veterinarski medicini (CVMP) je bilo sprejeto 16.07.2008 odločba Komisije pa 26.09.2008.
OPINION FOLLOWING AN ARTICLE 35 REFERRAL FOR SODIUM SALICYLATE 
ODBOR ZA ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI (CVMP) MNENJE V ZVEZI Z NAPOTITVIJO V SKLADU S ČLENOM 35 ZA ZDRAVILO NATRIJEV SALICILAT
--1Live attenuated bovine respiratory syncytial virus (BRSV), strain Lym-56 104.7 - 6.5 CCID50* *Cell culture infectious dose 50% 
--1 živ oslabljen bovini respiratorni sincicijski virus (BRSV), sev Lym-56 104,7-6,5 CCID50* * 50-% infektivni odmerek v celični kulturi
Immediate packaging 
Način uporabe Pakiranje za takojšnjo uporabo
Package size Withdraw al period 
Velikost pakiranja
Intravenous use vial (glass) 
4,5 mg/ml koncentrat za raztopino za infundiranje intravenska uporaba viala (steklena)
(Invented) name Strength Pharmaceutical Form Route of Administration 
Številka EU (Izmišljeno) ime Jakost
hours before taking the other. 
3 ure, preden vzamete drugo.
Date of first authorisation: 16 September 1998 Date of latest renewal: 3 September 2008 
Datum prve odobritve: 16. september 1998 Datum zadnjega podaljšanja: 3. september 2008
After taking one of them, wait at least 2 to 3 
Po zaužitju enega od teh zdravil počakajte vsaj 2 do
Comtess and iron supplements at the same time. 
Comtess in dodatkov železa istočasno.
• binge eating (eating large amounts of food in a short time period) or compulsive eating (eating more food than normal and more than is needed to satisfy your hunger). 
• prenajedanje (uživanje velikih količin hrane v kratkem času) ali kompulzivno prenajedanje (uživanje večjih količin hrane kot običajno oziroma več, kot je potrebno za potešitev lakote).
• altered or increased sexual interest and behaviour of significant concern to you or to others, for example, an increased sexual drive; 
• spremenjeno ali povečano zanimanje za spolnost in zaskrbljujoče spolno vedenje, na primer povečano spolno slo;
• if you are taking certain antidepressants (ask your doctor or pharmacist whether your antidepressive medicine can be taken together with Comtess); 
• če jemljete določene antidepresive (povprašajte svojega zdravnika ali farmacevta, ali lahko jemljete svoje zdravilo proti depresiji skupaj z zdravilom Comtess);
What Comtess is and what it is used for 
Kaj je zdravilo Comtess in za kaj ga uporabljamo
EU/1/98/082/001 30 film-coated tablets EU/1/98/082/002 60 film-coated tablets EU/1/98/082/003 100 film-coated tablets EU/1/98/082/005 175 film-coated tablets 
EU/1/98/082/001 30 filmsko obloženih tablet EU/1/98/082/002 60 filmsko obloženih tablet EU/1/98/082/003 100 filmsko obloženih tablet EU/1/98/082/005 175 filmsko obloženih tablet
The safety and efficacy of Comtess in children below age 18 have not been established. 
Varnost in učinkovitost zdravila Comtess pri otrocih, starih do 18 let, nista bili dokazani.
If you stop taking Comtess Do not stop taking Comtess unless your doctor tells you to. 
Če ste prenehali jemati zdravilo Comtess Ne prekinite jemanja zdravila Comtess, razen če vam to naroči vaš zdravnik.
Do not use Comtess during pregnancy or if you are breast-feeding. 
Ne jemljite zdravila Comtess v nosečnosti ali če dojite.
If you experience such effects at the start of treatment with Comtess you should contact your doctor who may decide to adjust your dosage of levodopa. 
Če pri vas pride od takih učinkov na začetku zdravljenja z zdravilom Comtess, morate obvestiti zdravnika, ki se bo morda odločil, da vam prilagodi odmerjanje levodope.
Other medicines and Comtess 
Druga zdravila in zdravilo Comtess
What you need to know before you take Comtess 
Kaj morate vedeti, preden boste vzeli zdravilo Comtess
There are large intra- and interindividual variations in the absorption of entacapone. 
V absorpciji entakapona so velike intra- in interindividualne variacije.
If you forget to take Comtess 
Če ste pozabili vzeti zdravilo Comtess
Comtess in association with levodopa may have a major influence on the ability to drive and use machines. 
Comtess ima skupaj z levodopo pomemben vpliv na sposobnost vožnje in upravljanja s stroji.
Do not take Comtess 
Ne jemljite zdravila Comtess
What Comtess is and what it is used for What you need to know before you take Comtess How to take Comtess 
Kaj je zdravilo Comtess in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Comtess Kako jemati zdravilo Comtess Možni neželeni učinki
If you forget to take the Comtess tablet with your levodopa dose, you should continue the treatment by taking the next Comtess tablet with your next levodopa dose. 
Če pozabite vzeti tableto Comtess s svojim odmerkom levodope, nadaljujte zdravljenje tako, da vzamete naslednjo tableto Comtess z naslednjim odmerkom levodope.
White high-density polyethylene (HDPE) bottles with white tamper proof polypropylene (PP) closures containing 30, 60, 100 or 175 tablets. 
Bele stekleničke iz polietilena visoke gostote (HDPE), z belim polipropilenskim (PP) pokrovčkom, odpornim proti nepooblaščenemu odpiranju, v katerih je po 30, 60, 100 ali 175 tablet.
When Comtess is given at higher doses: 
Pri uporabi višjih odmerkov zdravila Comtess:
comtess 200 mg [carton only] 
comtess 200 mg [samo na škatli]
If you take more Comtess than you should In the event of an overdose, consult your doctor, pharmacist or the nearest hospital immediately. 
Če ste vzeli večji odmerek zdravila Comtess, kot bi smeli Če ste vzeli prevelik odmerek, se takoj posvetujte z zdravnikom, farmacevtom ali najbližjo bolnišnico.
• dizziness, tiredness, increased sweating, fall ; 
• omotičnost, utrujenost, povečano znojenje, padec;
General characteristics of the active substance Absorption 
Splošne značilnosti zdravilne učinkovine Absorpcija
Comtess may make it harder for you to digest iron. 
Zdravilo Comtess lahko oteži prebavljanje železa.
As Comtess tablets will be taken together with other levodopa medicines, please also read the package leaflets of these medicines carefully. 
Ker boste tablete Comtess jemali skupaj z drugimi zdravili z levodopo, skrbno preberite tudi njihova navodila za uporabo.
Comtess tablets contain entacapone and are used together with levodopa to treat Parkinson's disease. 
Tablete Comtess vsebujejo entakapon in jih uporabljamo skupaj z levodopo za zdravljenje Parkinsonove bolezni.